V173M (p.Val173Met) variant of TP53 (Cellular tumor antigen p53)
V173M (p.Val173Met) in TP53 (Cellular tumor antigen p53) is a missense change. Clinical records from ClinVar, EBI, and UniProt describe it as pathogenic in the context of Li-Fraumeni syndrome. The available variant effect predictions contribute to a CATVariant prioritization score of 0.87 / 1. The record also includes population frequency data, experimental measurements, published literature, and structural context.
V173M (p.Val173Met) variant details
- p.Val173Met
- rs876660754
- ClinGen CA10577579
- NCI-TCGA Cosmic COSV5267
- Pathogenic
- Li-Fraumeni syndrome
- Missense
- Variant Prioritization Score for Impact Estimate 0.866
- REVEL 0.89
- ESM-1b 1.00
- AlphaMissense 1.00
- CADD 24.80
- PolyPhen-2 0.95
- SIFT 0.02
- ClinVar: Pathogenic (Li-Fraumeni syndrome)
- EBI: Pathogenic (in LFS)
- UniProt: Pathogenic (in LFS)
- Most common in the HGDP:BERGAMOITALIAN population (allele frequency 0.045)
- Structural context available
- p53 variant effect measured by cell growth: score -1.24
- Cited in: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic… (PMID 25394175)
- Cited in: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. (PMID 17392385)